{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T07:35:21Z","timestamp":1793432121215,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ejso.2024.108790","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T06:48:45Z","timestamp":1729838925000},"page":"108790","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["HIPEC for metastatic gastric cancer: Moving the needle towards 3-year survival"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6288-2788","authenticated-orcid":false,"given":"Neal","family":"Bhutiani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6837-5018","authenticated-orcid":false,"given":"Y. David","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen A.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5022-5505","authenticated-orcid":false,"given":"Michael G.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naruhiko","family":"Ikoma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul F.","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0882-9860","authenticated-orcid":false,"given":"Jenny J.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariela Blum","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaffer A.","family":"Ajani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian D.","family":"Badgwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ejso.2024.108790_bib1","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1245\/s10434-017-5838-y","article-title":"Patterns of initial recurrence in gastric adenocarcinoma in the era of preoperative therapy","volume":"24","author":"Ikoma","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"10.1016\/j.ejso.2024.108790_bib2","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/S1470-2045(16)30500-9","article-title":"Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database","volume":"17","author":"Franko","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2024.108790_bib3","unstructured":"Surveillance E, and End Results Program. SEER\u2217Explorer: An interactive website for SEER cancer statistics. National Cancer Institute. Accessed September 14, 2023. https:\/\/seer.cancer.gov\/statistics-network\/explorer\/."},{"issue":"957","key":"10.1016\/j.ejso.2024.108790_bib4","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1136\/pgmj.2004.029330","article-title":"Epidemiology of gastric cancer in Japan","volume":"81","author":"Inoue","year":"2005","journal-title":"Postgrad Med"},{"issue":"3","key":"10.1016\/j.ejso.2024.108790_bib5","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3322\/caac.21657","article-title":"Current treatment and recent progress in gastric cancer","volume":"71","author":"Joshi","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"19","key":"10.1016\/j.ejso.2024.108790_bib6","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1200\/JCO.2018.77.8613","article-title":"Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial","volume":"36","author":"Ishigami","year":"2018","journal-title":"J Clin Oncol : Offic J Am Soci Clinic Oncol"},{"key":"10.1016\/j.ejso.2024.108790_bib7","doi-asserted-by":"crossref","first-page":"S1040","DOI":"10.1016\/j.annonc.2021.08.1485","article-title":"1376O the effect of hyperthermic intraperitoneal chemotherapy (HIPEC) upon cytoreductive surgery (CRS) in gastric cancer (GC) with synchronous peritoneal metastasis (PM): a randomized multicentre phase III trial (GASTRIPEC-I-trial)","volume":"32","author":"Rau","year":"2021","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.ejso.2024.108790_bib8","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1016\/j.ejso.2021.05.016","article-title":"Prognostic impact of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in gastric cancer patients: a meta-analysis of randomized controlled trials","volume":"47","author":"Granieri","year":"2021","journal-title":"Eur J Surg Oncol : J Europ Soci Surgic Oncol British Assoc Surgic Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2024.108790_bib9","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1002\/cam4.2204","article-title":"Hyperthermic intraperitoneal chemotherapy (HIPEC) in combined treatment of locally advanced and intraperitonealy disseminated gastric cancer: a retrospective cooperative Central-Eastern European study","volume":"8","author":"Yarema","year":"2019","journal-title":"Cancer Med"},{"issue":"23","key":"10.1016\/j.ejso.2024.108790_bib10","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.18.01688","article-title":"Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis","volume":"37","author":"Bonnot","year":"2019","journal-title":"J Clin Oncol : Offic. J. Am. Soci. Clinic. Oncol."},{"issue":"1","key":"10.1016\/j.ejso.2024.108790_bib11","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s00464-017-5668-9","article-title":"Lessons learned from a phase II clinical trial of laparoscopic HIPEC for gastric cancer","volume":"32","author":"Badgwell","year":"2018","journal-title":"Surg Endosc"},{"issue":"11","key":"10.1016\/j.ejso.2024.108790_bib12","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1245\/s10434-017-6047-4","article-title":"Phase II trial of laparoscopic hyperthermic intraperitoneal chemoperfusion for peritoneal carcinomatosis or positive peritoneal cytology in patients with gastric adenocarcinoma","volume":"24","author":"Badgwell","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2024.108790_bib13","first-page":"692","article-title":"Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity","volume":"104","author":"Gill","year":"2011"},{"issue":"6","key":"10.1016\/j.ejso.2024.108790_bib14","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1245\/s10434-011-1631-5","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial","volume":"18","author":"Yang","year":"2011","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2024.108790_bib15","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1186\/s12885-019-5640-2","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, the study protocol of a multicentre randomised controlled trial (PERISCOPE II)","volume":"19","author":"Koemans","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejso.2024.108790_bib16","first-page":"S1040","volume":"vol. 32","author":"Rau","year":"2021"},{"issue":"1","key":"10.1016\/j.ejso.2024.108790_bib17","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1245\/s10434-020-08739-5","article-title":"A phase II trial of cytoreduction, gastrectomy, and hyperthermic intraperitoneal perfusion with chemotherapy for patients with gastric cancer and carcinomatosis or positive cytology","volume":"28","author":"Badgwell","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"10.1016\/j.ejso.2024.108790_bib18","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1200\/JCO.2007.13.9378","article-title":"Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie","volume":"26","author":"Al-Batran","year":"2008","journal-title":"J Clin Oncol : Offic. J. Am. Soci. Clinic. Oncol."},{"issue":"10418","key":"10.1016\/j.ejso.2024.108790_bib19","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","article-title":"Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial","volume":"402","author":"Janjigian","year":"2023","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ejso.2024.108790_bib20","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2024.108790_bib21","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41416-018-0150-6","article-title":"Randomised phase II trial to investigate catumaxomab (anti-EpCAM \u00d7 anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer","volume":"119","author":"Kn\u00f6dler","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejso.2024.108790_bib22","first-page":"217","volume":"vol. 20","author":"Sano","year":"2017"},{"issue":"9688","key":"10.1016\/j.ejso.2024.108790_bib23","first-page":"477","volume":"374","author":"Hartgrink","year":"2009","journal-title":"Gastric Cancer"},{"issue":"3","key":"10.1016\/j.ejso.2024.108790_bib24","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/bjs.7812","article-title":"Prognostic significance of peritoneal washing cytology in patients with gastric cancer","volume":"99","author":"Lee","year":"2011","journal-title":"Br J Surg"},{"issue":"10","key":"10.1016\/j.ejso.2024.108790_bib25","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1093\/bjs\/znab200","article-title":"Prognosis of poorly cohesive gastric cancer after complete cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (CYTO-CHIP study)","volume":"108","author":"Bonnot","year":"2021","journal-title":"Br J Surg"},{"issue":"3","key":"10.1016\/j.ejso.2024.108790_bib26","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41575-022-00703-w","article-title":"Current developments in gastric cancer: from molecular profiling to treatment strategy","volume":"20","author":"Alsina","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.ejso.2024.108790_bib27","first-page":"2033","article-title":"Advances in HER2-targeted therapy: novel agents and opportunities beyond breast and gastric cancer","volume":"25","author":"Meric-Bernstam","year":"2019"},{"issue":"12","key":"10.1016\/j.ejso.2024.108790_bib28","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.5858\/arpa.2016-0331-CP","article-title":"HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the college of American pathologists, American society for clinical pathology, and American society of clinical Oncology","volume":"140","author":"Bartley","year":"2016","journal-title":"Arch Pathol Lab Med"},{"issue":"5","key":"10.1016\/j.ejso.2024.108790_bib29","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/modpathol.2011.198","article-title":"HER2 testing in gastric cancer: a practical approach","volume":"25","author":"R\u00fcschoff","year":"2012","journal-title":"Mod Pathol"},{"issue":"9","key":"10.1016\/j.ejso.2024.108790_bib30","first-page":"1523","article-title":"HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target","volume":"19","author":"Gravalos","year":"2008"},{"issue":"5","key":"10.1016\/j.ejso.2024.108790_bib31","first-page":"1115","article-title":"Optimized PD-L1 scoring of gastric cancer","volume":"24","author":"Schoemig-Markiefka","year":"2021"},{"key":"10.1016\/j.ejso.2024.108790_bib32","volume":"vol. 11","author":"Xie","year":"2021"},{"issue":"3","key":"10.1016\/j.ejso.2024.108790_bib33","first-page":"661","article-title":"PD-L1 testing in gastric cancer by the combined positive score of the 22C3 PharmDx and SP263 assay with clinically relevant cut-offs","volume":"52","author":"Park","year":"2020"},{"issue":"6","key":"10.1016\/j.ejso.2024.108790_bib34","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/jamaoncol.2021.0275","article-title":"Assessment of pembrolizumab therapy for the treatment of microsatellite instability\u2013high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials","volume":"7","author":"Chao","year":"2021","journal-title":"JAMA Oncol"},{"issue":"10294","key":"10.1016\/j.ejso.2024.108790_bib35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejso.2024.108790_bib36","first-page":"86","volume":"vol. 8","author":"Yasui","year":"2005"},{"key":"10.1016\/j.ejso.2024.108790_bib37","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/1471-2407-14-183","article-title":"GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase III study","volume":"14","author":"Glehen","year":"2014","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.ejso.2024.108790_bib38","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s12885-020-6701-2","volume":"20","author":"Beeharry","year":"2020","journal-title":"BMC Cancer"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798324008588?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798324008588?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:47:06Z","timestamp":1740124026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798324008588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0748798324008588"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2024.108790","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HIPEC for metastatic gastric cancer: Moving the needle towards 3-year survival","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2024.108790","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108790"}}